Yellow eyes (jaundice) - Causes, Treatment & When to See a Doctor

```html

What is Yellow eyes (jaundice)?

Jaundice is a visible yellowing of the skin, mucous membranes, and especially the whites of the eyes (sclerae). The discoloration occurs when there is an excess of bilirubin—a yellow pigment that is a by‑product of the normal breakdown of red blood cells—in the bloodstream. Under normal circumstances the liver processes bilirubin and excretes it in the stool. When this pathway is disrupted, bilirubin builds up, tinting the eyes and skin yellow.

While the term “jaundice” often refers to the whole body, many people first notice the change in the eyes because the sclerae are thin and the yellow color is striking. Yellow eyes can signal anything from a harmless, temporary condition to a serious liver or blood disorder, so understanding the underlying cause is essential.

Common Causes

Jaundice results from three broad mechanisms: over‑production of bilirubin, impaired processing by the liver, or obstruction of bilirubin flow. Below are the most frequent conditions associated with yellow eyes.

• Acute viral hepatitis (A, B, C, D, E): Inflammation of the liver hampers bilirubin conjugation and excretion.
• Alcoholic or non‑alcoholic fatty liver disease (NAFLD): Fat accumulation damages liver cells, reducing bilirubin clearance.
• Gallstones or biliary obstruction: Stones or tumors block the bile ducts, causing bilirubin to back up into the blood.
• Hemolytic anemia: Accelerated destruction of red blood cells releases large amounts of bilirubin.
• Gilbert’s syndrome: A common, benign genetic variant that mildly reduces the liver’s ability to process bilirubin.
• Medication‑induced liver injury: Certain drugs (e.g., acetaminophen overdose, isoniazid, certain antibiotics) can cause toxic hepatitis.
• Pancreatic cancer (especially at the head of the pancreas): Tumor can compress the common bile duct.
• Sepsis or severe infection: Systemic inflammation can impair liver function and promote hemolysis.
• Newborn physiologic jaundice: Immature liver enzymes in infants lead to temporary bilirubin buildup.
• Autoimmune hepatitis: The body’s immune system attacks liver cells, decreasing bilirubin processing.

Associated Symptoms

Jaundice rarely occurs in isolation. Other signs often point to the underlying disease.

• Dark urine (bilirubin excreted in urine)
• Pale, clay‑colored stools (blocked bile flow)
• Upper‑right abdominal pain or tenderness
• Fatigue, weakness, or malaise
• Pruritus (itchy skin) – common with cholestasis
• Unexplained weight loss
• Fever or chills (suggesting infection)
• Swelling of the abdomen (ascites) or legs (edema)
• Confusion or difficulty concentrating (hepatic encephalopathy in severe liver disease)
• Joint or muscle aches (often seen with viral hepatitis)

When to See a Doctor

Prompt evaluation is warranted if any of the following appear alongside yellow eyes:

• Yellowing of the skin, not just the eyes.
• Dark urine or pale stools.
• Severe abdominal pain, especially in the upper‑right quadrant.
• Fever, chills, or a feeling of being “very ill.”
• Persistent nausea, vomiting, or loss of appetite for more than 48 hours.
• Confusion, slurred speech, or difficulty staying awake.
• Unexplained weight loss or swelling of the abdomen/legs.
• Recent travel to areas with hepatitis A/E risk or exposure to contaminated food/water.

If you notice any of these, contact a primary‑care provider or visit an urgent‑care center without delay.

Diagnosis

Healthcare professionals use a stepwise approach to identify the cause of jaundice.

1. Clinical history & physical exam

• Detailed medication, alcohol, and supplement review.
• Travel, occupational, and family‑history inquiries (e.g., hereditary liver disease).
• Physical signs: liver size, tenderness, spleen enlargement, stigmata of chronic liver disease (spider angiomas, palmar erythema).

2. Laboratory tests

Test	What it tells you
Serum bilirubin (total & direct)	Distinguishes unconjugated (pre‑hepatic) vs. conjugated (hepatic/cholestatic) jaundice.
ALT, AST, ALP, GGT	Enzyme pattern points to hepatocellular injury (ALT/AST ↑) or cholestasis (ALP/GGT ↑).
Complete blood count (CBC)	Detects hemolysis (low Hb, high reticulocyte count) or infection.
Hemolysis panel (LDH, haptoglobin, peripheral smear)	Confirms red‑cell breakdown.
Viral hepatitis serologies (HAV, HBV, HCV, HEV)	Identify infectious causes.
Autoimmune markers (ANA, SMA, LKM‑1)	Screen for autoimmune hepatitis.

3. Imaging studies

• Ultrasound: First‑line to view gallstones, bile‑duct dilation, liver texture.
• CT or MRI: Detailed anatomy, especially for pancreas or tumor evaluation.
• MRCP (magnetic resonance cholangiopancreatography): Non‑invasive view of bile ducts.

4. Specialized procedures

• Endoscopic retrograde cholangiopancreatography (ERCP): Diagnostic and therapeutic for ductal obstruction.
• Liver biopsy: Reserved for unclear cases; distinguishes fibrosis, cirrhosis, or specific hepatitis types.

Treatment Options

Treatment depends on the underlying cause. Below are the most common therapeutic pathways.

1. Addressing the root cause

• Viral hepatitis: Antiviral agents (e.g., sofosbuvir/velpatasvir for HCV, tenofovir for HBV), supportive care, and vaccination for hepatitis A/E prevention.
• Gallstones or biliary obstruction: Endoscopic stone removal (ERCP), laparoscopic cholecystectomy, or stent placement.
• Hemolytic anemia: Treat trigger (e.g., stop offending drug), corticosteroids for immune‑mediated hemolysis, or transfusion if severe.
• Alcoholic liver disease: Abstinence, nutritional support, and possibly corticosteroids for severe alcoholic hepatitis.
• Medication‑induced injury: Immediate discontinuation of offending agent; N‑acetylcysteine for acetaminophen toxicity.
• Pancreatic cancer: Multidisciplinary approach—surgery, chemotherapy, radiation, or palliative stenting to relieve jaundice.

2. Symptomatic management

• Pruritus: Cholestyramine, antihistamines, or rifampin for refractory itch.
• Hydration & nutrition: Maintain adequate fluid intake; low‑fat diet if bile flow is compromised.
• Phototherapy (newborns): Blue‑light therapy safely converts bilirubin to water‑soluble forms.

3. Supportive measures

• Vitamin K supplementation if coagulopathy develops.
• Monitoring for hepatic encephalopathy—lactulose or rifaximin if needed.
• Regular follow‑up labs to track bilirubin trends.

Prevention Tips

While some causes (genetic conditions, newborn physiologic jaundice) cannot be prevented, many are modifiable.

• Vaccinate: Hepatitis A and B vaccines are highly effective.
• Limit alcohol intake: No more than 1 drink per day for women, 2 for men, or abstain if liver disease exists.
• Maintain a healthy weight: Reduces risk of NAFLD.
• Practice safe food and water hygiene: Especially when traveling to endemic regions for hepatitis E.
• Use medications responsibly: Follow dosing guidelines, avoid unnecessary over‑the‑counter pain relievers, and inform providers of all supplements.
• Screen for high‑risk conditions: Regular hepatitis testing for people with IV drug use, multiple sexual partners, or occupational exposure.
• Promptly treat infections: Early antibiotics for bacterial cholangitis can prevent biliary sepsis.

Emergency Warning Signs

Key Takeaways

Yellow eyes, or jaundice, are a visible sign that bilirubin metabolism is disrupted. Because the underlying reasons range from benign (Gilbert’s syndrome) to life‑threatening (fulminant hepatitis, biliary obstruction), recognizing associated symptoms and obtaining timely medical evaluation are crucial. A thorough history, focused lab work, and targeted imaging usually pinpoint the cause, allowing for specific treatment—whether antiviral therapy, stone removal, medication adjustment, or supportive care. Lifestyle measures such as vaccination, alcohol moderation, weight control, and safe medication practices can prevent many of the most common, avoidable causes.

For personalized advice, always consult a qualified health professional. This article is for educational purposes and does not replace professional medical diagnosis or treatment.

```